Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

NCT07365410 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)
Brain Metastases
Furmonertinib
EGFR Mutation

Interventions

DRUG: Furmonertinib
DRUG: Furmonertinib
DRUG: carboplatin
DRUG: pemetrexed

Sponsor

Tianjin Medical University Cancer Institute and Hospital